Annual Financial Performance FY 2025-26
Eris Lifesciences Limited reported strong consolidated financial results for FY 2025-26 with revenue reaching ₹3,129.42 crore, representing 8.1% YoY growth from ₹2,893.64 crore. Net profit surged 76% to ₹619.52 crore from ₹351.84 crore in the previous year, driven by operational efficiency and strategic acquisitions. EBITDA grew 10.1% to ₹1,120 crore with margin expansion to 35.8% (60 bps improvement). The domestic branded formulations business showed particularly strong performance with revenue of ₹2,778 crore (11% growth) and EBITDA margin of 37%.
Strategic Acquisitions and Business Expansion
The company completed several significant acquisitions during the period, including acquiring the remaining 30% stake in Swiss Parenterals Limited through a preferential allotment of 23,06,372 equity shares (consideration ₹423.33 crore), making it a wholly-owned subsidiary. Additionally, Eris acquired Velbiom's probiotics business for ₹50 crore on a slump sale basis. These acquisitions built upon previous strategic moves including the acquisition of insulin brands Basalog and Insugen from Biocon Biologics Limited for ₹1,242 crore in FY 2024-25. Total goodwill stood at ₹911.97 crore as of March 31, 2026.
Operational Highlights and Market Position
Eris significantly strengthened its insulin franchise, with market share increasing from 9% to 16% post-Biocon acquisition. The company achieved the #1 rank by volume in the GLP-1 semaglutide segment following its launch of Sundae as an affordable weekly injection. Manufacturing capacity expansion included substantial investments in the Bhopal facility, scaling to 133M vials and 75M cartridges capacity with additional mAbs production capabilities. The company maintained industry-leading domestic formulations EBITDA margin of 37% with Yield Per Man of ₹5.7 lakh.
Capital Structure and Corporate Actions
Share capital increased to 13,85,42,887 equity shares (₹13.85 crore) through ESOP issuances and acquisition-related allotments. Major shareholders included Amit Indubhushan Bakshi (42.12%), HDFC Small Cap Fund (8.46%), and Lilac Investments Limited (8.64%). Total borrowings stood at ₹2,309.68 crore, including ₹1,250 crore in non-convertible debentures at 8.73%. The Board declared no dividend for FY26 but announced an interim dividend of ₹7.21 per share (721%) for FY 2026-27.
ESG and Sustainability Reporting
The company published its comprehensive Business Responsibility and Sustainability Report (BRSR) disclosing robust ESG metrics. Key achievements included zero work-related injuries or fatalities, 100% safety assessments at all facilities, and strong environmental performance with 93.5% waste recycling rate. GHG emissions totaled 2,367.48 TCO₂e with intensity of 1.33 × 10⁻⁷ TCO₂e/₹ turnover. Water management initiatives included rainwater harvesting and zero liquid discharge through effluent recycling. CSR expenditure totaled ₹7.99 crore focused on preventive medical screening and education initiatives.
Governance and Regulatory Compliance
The company faced regulatory penalties of ₹65,000 each by BSE and NSE for non-compliance with Regulation 17(1) regarding board composition, with appeals filed against these penalties. Board changes included the retirement of Mr. Rajeev Dalal (Independent Director) and appointment of Mr. Vineet Varma as Independent Director. Auditors provided unmodified opinions on both standalone and consolidated financial statements, with reasonable assurance on BRSR core indicators. Contingent liabilities totaled ₹51.57 crore, primarily comprising DPCO matters (₹20.91 crore) and tax/GST matters.
Accounting Impacts and Forward Outlook
Implementation of new Labor Codes increased gratuity and leave liabilities by ₹17.24 crore, recognized as an exceptional item. The group's opt-in for the concessional tax regime under Income Tax Act 2025 resulted in a deferred tax credit of ₹150 crore. The report contains forward-looking statements emphasizing focus on disciplined execution, operational excellence, and high-margin businesses while navigating the evolving external environment. The 20th Annual General Meeting is scheduled for September 25, 2026, to be conducted through video conferencing.